The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Role of Reduced Suppression of Glucose Production and Diminished Early Insulin Release in Impaired Glucose Tolerance
Open accessAbstract
BACKGROUND: Insulin resistance and impaired insulin secretion both occur in non-insulin-dependent diabetes (NIDDM), but their relative importance is unclear. Hyperglycemia itself has adverse effects on tissue insulin sensitivity and insulin secretion that make it difficult to distinguish between primary and secondary abnormalities. To avoid this problem we studied subjects with postprandial glucose intolerance but not sustained hyperglycemia. METHODS: We compared the rate of systemic appearance and disappearance of glucose, the output of endogenous hepatic glucose, splanchnic and muscle uptake of glucose, and plasma insulin and glucagon responses after the ingestion of 1 g of glucose per kilogram of body weight in 15 subjects with impaired glucose tolerance (8 of them nonobese and 7 obese) and in 16 normal subjects (9 nonobese and 7 obese) who were matched for age and weight. RESULTS: After glucose ingestion the mean (+/- SE) rate of total systemic appearance of glucose was significantly higher in both the nonobese subjects (455 +/- 12 mmol per five hours) and the obese subjects (486 +/- 17 mmol per five hours) with impaired glucose tolerance than in the respective normal subjects (411 +/- 11 and 436 +/- 7 mmol per five hours). This difference was fully accounted for by the reduced suppression of endogenous hepatic glucose in the subjects with impaired glucose tolerance (a reduction of about 28 percent, vs. 48 percent in the normal subjects; P less than 0.01). Despite late hyperinsulinemia, at 30 minutes the subjects with impaired glucose tolerance had smaller increases in plasma insulin and smaller reductions in plasma glucagon (both P less than 0.01). Molar ratios of plasma insulin to plasma glucagon levels correlated inversely (r = -0.62, P less than 0.001) with the rates of systemic glucose appearance; the latter correlated positively (r = 0.72, P less than 0.0001) with peak plasma glucose concentrations. CONCLUSIONS: Impaired glucose tolerance, the precursor of NIDDM, results primarily from reduced suppression of hepatic glucose output due to abnormal pancreatic islet-cell function. The late hyperinsulinemia may be the consequence of an inadequate early beta-cell response rather than of insulin resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“As indicated by several studies, insulin resistance leads to basal-fasting hyperinsulinemia, which may result in the insensitivity of beta-cell secretion. This insensitivity leads to a lower first-phase insulin secretion to the rising postprandial glucose but a subsequent exaggerated compensatory second-phase insulin secretion, which might result in hypoglycemia [2, 3].”
From Associated Factors with Biochemical Hypoglycemia during an Oral Glucose Tolerance Test in a Chinese Population (2017) · cites this paper as [3]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“When the first-phase insulin response decreases, firstly, blood glucose starts to rise after the meal, which leads to late but excessive secretion of the second-phase insulin secretion. Thus, late reactive hypoglycemia occurs.[3]”
From Postprandial Reactive Hypoglycemia (2019) · cites this paper as [3]
Experimental — accuracy not yet measuredIn the citing paper
“Indeed, with better matching of subjects for age, sex and obesity, there also does seem to be a decrease of the insulinogenic index in subjects with IGT [5, 87, 88].”
From The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes (2003) · cites this paper as [5]
In the citing paper
“This reduction in the early insulin response results in a lack of adequate suppression of hepatic glucose production with subsequent post challenge hyperglycaemia and increased insulin concentrations late in the test [5, 126].”
From The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes (2003) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coated Charcoal Immunoassay of Insulin
Herbert, V. D., Lau, K., Gottlieb, C. W., & Bleicher, S. J. (1965) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-25-10-1375 · Cited by 2,969
The Triumvirate: β-Cell, Muscle, Liver: A Collusion Responsible for NIDDM
DeFronzo, R. A. (1988) · Diabetes · doi:10.2337/diab.37.6.667 · Cited by 2,456
Plasma Insulin Responses to Oral and Intravenous Glucose: Studies in Normal and Diabetic Subjects*
Perley, M. J., & Kipnis, D. M. (1967) · Journal of Clinical Investigation · doi:10.1172/jci105685 · Cited by 917
Early Metabolic Defects in Persons at Increased Risk for Non-Insulin-Dependent Diabetes Mellitus
Eriksson, J., Franssila-Kallunki, A., Ekstrand, A., Saloranta, C., Widén, E., Schalin, C., & Groop, L. (1989) · New England Journal of Medicine · doi:10.1056/nejm198908103210601 · Cited by 807
Rossetti, L., Giaccari, A., & DeFronzo, R. A. (1990) · Diabetes Care · doi:10.2337/diacare.13.6.610 · Cited by 774
Kolterman, O., Gray, R. S., Griffin, J., BURSTEIN, P. J., Insel, J. R., Scarlett, J. A., & Olefsky, J. M. (1981) · Journal of Clinical Investigation · doi:10.1172/jci110350 · Cited by 628
Impaired Glucose Tolerance as a Disorder of Insulin Action
Lillioja, S., Mott, D. M., Howard, B. V., Bennett, P. H., Yki-Järvinen, H., Freymond, D., Nyomba, B. L., Zurlo, F., Swinburn, B., & Bogardus, C. (1988) · New England Journal of Medicine · doi:10.1056/nejm198805123181901 · Cited by 578
METHODS FOR THE INVESTIGATION OF PERIPHERAL BLOOD FLOW
Greenfield, A. D. M., Whitney, R. J., & Mowbray, J. F. (1963) · British Medical Bulletin · doi:10.1093/oxfordjournals.bmb.a070026 · Cited by 494
Andres, R., Cader, G., & Zierler, K. L. (1956) · Journal of Clinical Investigation · doi:10.1172/jci103324 · Cited by 389
Glucagon physiology and pathophysiology in the light of new advances
Unger, R. H. (1985) · Diabetologia · doi:10.1007/bf00281991 · Cited by 361
Research works printed but not linked: 6
- Gerich, 1988, Clin Endocrinol Metab, 2, 307
- Luzi, 1989, Am J Physiol, 257, E241
- 1980, WHO Tech Rep Ser, 646, 1
- Faloona GR, Unger RH. Glucagon. In: Jaffe BM, Behrman HR, eds. Methods of hormone radioimmunoassay. New York: Academic Press, 1974:317–30
- Hetenyi, 1974, Fed Proc, 33, 1841
- Chiasson, 1977, Fed Proc, 36, 229
Cited by
Sorted by citations
Items 301–400 of 593
BRENNER, M., Gromada, J., Efanov, A. M., Bokvist, K. B., & MEST, H. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1304.042 · Cited by 21
Davies, M. J., Metcalfe, J., Day, J. L., Grenfell, A., Hales, C. N., & Gray, I. P. (1994) · Diabetic Medicine · doi:10.1111/j.1464-5491.1994.tb00233.x · Cited by 21
Forbes, S., Moonan, M., Robinson, S., Anyaoku, V., Patterson, M., Murphy, K. G., Ghatei, M. A., Bloom, S. R., & Johnston, D. G. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02172.x · Cited by 21
Féry, F., Mélot, C., & BALASSE, E. O. (1993) · Metabolism · doi:10.1016/0026-0495(93)90113-3 · Cited by 21
Nijpels, G., Popp‐Snijders, C., Kostense, P. J., Bouter, L. M., & Heine, R. J. (1997) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(97)00119-4 · Cited by 21
Can we make surrogate β-cells better than the original?
Weir, G. C. (2004) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2004.02.004 · Cited by 21
Treviño, S., Díaz, A., Sánchez‐Lara, E., Sarmiento-Ortega, V. E., Flores-Hernández, J. Á., Brambila, E., Meléndez, F. J., & Vergara, E. G. (2018) · Bioinorganic Chemistry and Applications · doi:10.1155/2018/2151079 · Cited by 20
Nyblom, H. K., Nord, L. I., Andersson, R., Kenne, L., & Bergsten, P. (2007) · NMR in Biomedicine · doi:10.1002/nbm.1197 · Cited by 21
Physiological endocrine control of energy homeostasis and postprandial blood glucose levels.
Gagliardino, J. J. (2005) · PubMed · Cited by 21
Ethnicity affects the postprandial regulation of glycogenolysis
Balasubramanyam, A., McKay, S. V., Nadkarni, P., Rajan, A. S., Garza, A., Pavlik, V., Herd, J. A., Jahoor, F., & Reeds, P. J. (1999) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1999.277.5.e905 · Cited by 20
The case for metabolic hypertension: Is it time to restructure the hypertension paradigm?
Pool, P. E. (1993) · Progress in Cardiovascular Diseases · doi:10.1016/0033-0620(93)90020-e · Cited by 20
Shiba, Y., Yamasaki, Y., Kubota, M., Matsuhisa, M., Tomita, T., Nakahara, I., Morishima, T., Kawamori, R., & Hori, M. (1998) · Metabolism · doi:10.1016/s0026-0495(98)90343-2 · Cited by 20
Hirose, T., Mizuno, R., & Yoshimoto, T. (2002) · Endocrine Journal · doi:10.1507/endocrj.49.649 · Cited by 20
Genetics of type 2 diabetes mellitus.
So, W., Ng, M. C. Y., Lee, S. C., Sanke, T., Lee, H. K., & Chan, J. C. N. (2000) · PubMed · Cited by 20
Postprandial Suppression of Glucagon Secretion: A Puzzlement
Geary, N. (2017) · Diabetes · doi:10.2337/dbi16-0075 · Cited by 18
Matsumoto, A., Kuwata, H., Kimura, S., Matsumoto, H., Ochi, K., Moro‐oka, Y., Watanabe, A., Yamada, H., Ishii, H., Miyazawa, T., et al. (2020) · Communications Biology · doi:10.1038/s42003-020-1026-x · Cited by 19
Koopal, C., Marais, A. D., Westerink, J., van der Graaf, Y., & Visseren, F. L. J. (2017) · Journal of Lipid Research · doi:10.1194/jlr.m076901 · Cited by 19
Motala, A. A., & Omar, M. A. K. (1994) · Diabetic Medicine · doi:10.1111/j.1464-5491.1994.tb00303.x · Cited by 19
Dagogo-Jack, S. E. (2025) · Diabetes · doi:10.2337/dbi25-0006 · Cited by 22
Eliasson, B., Rawshani, A., Axelsen, M., Hammarstedt, A., & Smith, U. (2017) · PLoS ONE · doi:10.1371/journal.pone.0173654 · Cited by 18
Song, Y., Jin, D., Jiang, X., Lv, C., & Zhu, H. F. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.11.170 · Cited by 18
The OGTT as test for beta cell function?
Stümvoll, M., Fritsche, A., & Häring, H. (2001) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.2001.00828.x · Cited by 18
Matsumoto, K., Sakamaki, H., Izumino, K., Yano, M., Ueki, Y., Miyake, S., & Tominaga, Y. (2000) · Metabolism · doi:10.1053/meta.2000.8623 · Cited by 17
Shiba, T. (2003) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(03)00169-4 · Cited by 18
Barnett, A. H., Anderson, D. M., Shelley, S., Morgan, R. L., & Owens, D. R. (2004) · Diabetes Obesity and Metabolism · doi:10.1111/j.1462-8902.2004.00321.x · Cited by 18
Moh, M. A. M., Jung, C., Lee, B., Choi, D., Kim, B., Kim, C., Kang, S., & Mok, J. (2018) · Diabetes and Vascular Disease Research · doi:10.1177/1479164118810691 · Cited by 17
Yoshinaga, H., & Kosaka, K. (1996) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(96)01195-3 · Cited by 17
Ichikawa, K., Yamato, T., Ojima, K., Tsuji, A., Ishikawa, K., Kusama, H., & Kojima, M. (2002) · Clinical and Experimental Pharmacology and Physiology · doi:10.1046/j.1440-1681.2002.03682.x · Cited by 17
Effects of metformin in obese patients with impaired glucose tolerance
Scheen, A. J., Letiexhe, M. R., & Lefèbvre, P. J. (1995) · Diabetes/Metabolism Reviews · doi:10.1002/dmr.5610110511 · Cited by 17
Zhao, G., Wirth, D., Schmitz, I., & Meyer‐Hermann, M. (2017) · Nature Communications · doi:10.1038/s41467-017-01627-9 · Cited by 16
Chen, C., Hsu, K.-J., Chien, K., & Chen, J.-J. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.705282 · Cited by 18
Kume, S., Kondo, M., Maeda, S., Nishio, Y., Yanagimachi, T., Fujita, Y., Haneda, M., Kondo, K., Sekine, A., Araki, S.-I., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.10.038 · Cited by 17
Foghsgaard, S., Vedtofte, L., Andreasen, C. H., Andersen, E. S., Bahne, E., Bagger, J. I., Svare, J., Holst, J. J., Clausen, T. D., Mathiesen, E. R., et al. (2017) · Diabetologia · doi:10.1007/s00125-017-4265-8 · Cited by 19
Silvestre, M. P., Goode, J. P., Vlaskovsky, P., McMahon, C., Tay, A., & Poppitt, S. D. (2017) · Obesity Reviews · doi:10.1111/obr.12631 · Cited by 17
Rattarasarn, C., Leelawattana, R., & Soonthornpun, S. (2009) · Metabolism · doi:10.1016/j.metabol.2009.06.029 · Cited by 16
Weaver, J. U., Robertson, D., Atkin, S. L., & on behalf of The Nateglinide Glycaemic Control Investigators (2004) · Diabetes Obesity and Metabolism · doi:10.1111/j.1462-8902.2004.00353.x · Cited by 16
de Souza, C. J., Gagen, K., Chen, W., & Dragonas, N. (2001) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.2001.00115.x · Cited by 16
Comparison of three methods for the quantification of β-cell function and insulin sensitivity
Nijpels, G., van der Wal, P. S., Bouter, L. M., & Heine, R. J. (1994) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(94)90060-4 · Cited by 16
de Souza, C. J., Russo, P. A., Lozito, R. J., & Dunning, B. E. (2001) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.2001.00114.x · Cited by 16
Abnormalities in Insulin Secretion in Type 2 Diabetes Mellitus
Meas, T., & Guillausseau, P.-J. (2011) · Wiley eBooks · doi:10.1002/9780470910016.ch3 · Cited by 16
Rothkopf, M. M., Bilof, M. L., Haverstick, L. P., & Nusbaum, M. J. (2009) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2008.09.005 · Cited by 15
Training improves the response in glucose flux to exercise in postmenopausal women
Zarins, Z. A., Johnson, M. L., Faghihnia, N., Horning, M. A., Wallis, G. A., Fattor, J. A., & Brooks, G. A. (2009) · Journal of Applied Physiology · doi:10.1152/japplphysiol.91568.2008 · Cited by 15
Insulin secretion in health and disease: nutrients dictate the pace
Regazzi, R., Rodriguez‐Trejo, A., & Jacovetti, C. (2015) · Proceedings of The Nutrition Society · doi:10.1017/s0029665115004152 · Cited by 17
Shen, M., Wang, M., He, W., He, M., Qiao, N., Ma, Z., Ye, Z., Zhang, Q., Zhang, Y., Yang, Y., et al. (2018) · International Journal of Endocrinology · doi:10.1155/2018/3015854 · Cited by 15
Bistable insulin response: The win-win solution for glycemic control
Akhtar, J., Han, Y., Han, S., Lin, W., Cao, C., Ge, R., Babarinde, I. A., Jia, Q., Yuan, Y., Chen, G., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105561 · Cited by 16
Insulin secretion and action in different stages of glucose tolerance in Asian Indians
Snehalatha, C., Satyavani, K., Sivasankari, S., Viswanathan, V., & Ramachandran, A. (1999) · Diabetic Medicine · doi:10.1046/j.1464-5491.1999.00084.x · Cited by 16
Diabetes - Damages and Treatments
Rigobelo, E. C. (2011) · InTech eBooks · doi:10.5772/1823 · Cited by 15
Sten-Linder, M., Wedell, A., Iselius, L., Efendić, S., Luft, R., & Luthman, H. (1993) · Diabetologia · doi:10.1007/bf00399089 · Cited by 15
Gluconeogenesis in Type 2 Diabetes
Gerich, J. E., & Nurjhan, N. (1993) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-2910-1_18 · Cited by 15
Self-citationDipeptidyl peptidase 4 inhibition and vildagliptin therapy for type 2 diabetes
Prato, S. D. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01439.x · Cited by 15
Traitement médicamenteux du diabète de type 2recommandation de bonne pratique
(2007) · Diabetes & Metabolism · doi:10.1016/s1262-3636(07)80038-3 · Cited by 20
Parekh, S., Bodicoat, D. H., Brady, E., Webb, D., Mani, H., Mostafa, S., Levy, M. J., Khunti, K., & Davies, M. J. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.02.013 · Cited by 16
Mangiafico, S. P., Lim, S. H., Neoh, S. L., Massinet, H., Joannides, C. N., Proietto, J., Andrikopoulos, S., & Fam, B. C. (2011) · Journal of Endocrinology · doi:10.1530/joe-11-0126 · Cited by 14
A diet high in FODMAPs as a novel dietary strategy in diabetes?
Chu, N. H. S., Chan, J. C. N., & Chow, E. (2022) · Clinical Nutrition · doi:10.1016/j.clnu.2022.07.036 · Cited by 15
Factors responsible for elevation of 1-h postchallenge plasma glucose levels in Japanese men
Harada, N., Fukushima, M., Toyoda, K., Mitsui, R., Izuka, T., Taniguchi, A., Nakai, Y., Yamada, Y., Seino, Y., & Inagaki, N. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.04.011 · Cited by 15
Management of diabetes and pregnancy – When to start and what pharmacological agent to choose?
Hiersch, L., & Yogev, Y. (2014) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2014.04.020 · Cited by 14
Pathogenesis of Type 2 Diabetes Mellitus
DeFronzo, R. A. (2018) · Endocrinology · doi:10.1007/978-3-319-45015-5_8 · Cited by 14
Connexin 36 mediates blood cell flow in mouse pancreatic islets
Short, K. W., Head, W. S., & Piston, D. W. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00523.2013 · Cited by 12
Pathophysiology of Type 2 Diabetes Mellitus
Scheen, A. J., & Lefèbvre, P. J. (1996) · Handbook of experimental pharmacology · doi:10.1007/978-3-662-09127-2_2 · Cited by 14
The importance of early insulin secretion and its impact on glycaemic regulation
Garber, A. (2000) · International Journal of Obesity · doi:10.1038/sj.ijo.0801423 · Cited by 14
In vivo β-cell function at the transition to early non-insulin-dependent diabetes mellitus
Swinburn, B. A., Gianchandani, R. Y., Saad, M. F., & Lillioja, S. (1995) · Metabolism · doi:10.1016/0026-0495(95)90189-2 · Cited by 14
Pathogenesis of type 2 diabetes mellitus
DeFronzo, R. A. (2015) · Wiley eBooks · doi:10.1002/9781118387658.ch25 · Cited by 17
Kim, K.-T. (2012) · Cited by 14
Hepato-Incretin Function of GLP-1: Novel Concept and Target in Type 1 Diabetes
Ahrén, B. (2015) · Diabetes · doi:10.2337/db14-1671 · Cited by 13
Li‐Gao, R., Carlotti, F., de Mutsert, R., Vlieg, A. V. H., de Koning, E. J. P., Jukema, J. W., Rosendaal, F. R., van Dijk, K. W., & Mook‐Kanamori, D. O. (2019) · Diabetes · doi:10.2337/db19-0378 · Cited by 13
Defining the Importance of Daily Glycemic Control and Implications for Type 2 Diabetes Management
Bode, B. W. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.09.2055 · Cited by 12
Sun, M., Huang, X., Jiang, L., Yan, Y., Li, B., ZHONG, W., Chen, J., Zhang, Y., Wang, Z., Li, J., et al. (2013) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2013.1164 · Cited by 13
Insulin-like growth factor-1 is a negative modulator of glucagon secretion
Mancuso, E., Mannino, G. C., Fatta, C. D., Fuoco, A., Spiga, R., Andreozzi, F., & Sesti, G. (2017) · Oncotarget · doi:10.18632/oncotarget.18514 · Cited by 12
What Are Incretins, and How Will They Influence the Management of Type 2 Diabetes?
Bonde, L., Rosenstock, J., & Triplitt, C. L. (2006) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2006.12.s7-a.1 · Cited by 13
Atypical antipsychotic agents and increased risk of diabetes: class action or differential action?
Ananth, J., & Kolli, S. (2005) · Expert Opinion on Drug Safety · doi:10.1517/14740338.4.1.55 · Cited by 13
Glucose Effectiveness in Nondiabetic Relatives: Dysglycemia and β-Cell Function at 10 Years
Egede, M. B., Henriksen, J. E., Durck, T. T., Levin, K., Rantzau, C., Ward, G. M., Beck‐Nielsen, H., & ALFORD, F. P. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3273 · Cited by 12
Niederwanger, A., Ciardi, C., Tatarczyk, T., Khan, M. I., Hermann, M., Mittermair, C., Al‐Zoairy, R., Salzmann, K., & Pedrini, M. T. (2014) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.114.092023 · Cited by 12
Kozawa, J., Okita, K., Iwahashi, H., Yamagata, K., Imagawa, A., & Shimomura, I. (2013) · Endocrine Journal · doi:10.1507/endocrj.ej13-0018 · Cited by 12
.BETA.-cell Function is a Major Contributor to Oral Glucose Disposition in Obese Japanese Students
Asano, T., Yoshida, R., OGATA, H., Kokawa, K., OGIMOTO, M., Akehi, Y., Anzai, K., Ono, J., Tamura, K., HIDEHIRA, K., et al. (2007) · Endocrine Journal · doi:10.1507/endocrj.k07-016 · Cited by 12
Rakotoambinina, B., Delaisi, B., Laborde, K., Silly, C., Jacques de, B. L. I. C., Lenoir, G., & Robert, J. (1994) · Pediatric Research · doi:10.1203/00006450-199411000-00024 · Cited by 12
Pathogenesis of hyperglycaemia in type 2 diabetes
Mitrakou, A. (2002) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.2002.00204.x · Cited by 12
Self-citationExpression of miR-206 in human islets and its role in glucokinase regulation
Joglekar, M. V., Wong, W. K. M., Maynard, C.-L., Umrani, M. R., Martin, D., Loudovaris, T., Thomas, H. E., Dalgaard, L. T., & Hardikar, A. A. (2018) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00152.2018 · Cited by 12
Early-phase insulin secretion is disturbed in obese subjects with glucose intolerance
Mizuno, A., Arai, H., Fukaya, M., Sato, M., Yamanaka-Okumura, H., Takeda, E., & Doi, T. (2007) · Metabolism · doi:10.1016/j.metabol.2007.01.017 · Cited by 12
Addressing the insulin secretion defect: A logical first-line approach
Gerich, J. E. (2000) · Metabolism · doi:10.1053/meta.2000.17824 · Cited by 12
Self-citationInsulin resistance and impaired glucose tolerance
Alcolado, J. C., CLARK, P. M. S., Rees, A., Hales, C. N., Yudkin, J., & Coppack, S. W. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90778-1 · Cited by 12
Eriksson, J. W., Emad, R. A., Lundqvist, M., Abrahamsson, N., & Kjellsson, M. C. (2023) · Endocrine Connections · doi:10.1530/ec-22-0506 · Cited by 12
Faheem, H., Alawadhi, R., Basha, E., Ismail, R., Ibrahim, H. A., Elshamy, A. M., Motawea, S. M., Seleem, M. A., Elkordy, A. M., Homouda, A. A., et al. (2024) · Physiological Genomics · doi:10.1152/physiolgenomics.00072.2024 · Cited by 11
Glucose-incretin interaction revisited [Review]
Ishii, H., Sato, Y., Takei, M., Nishio, S., & Komatsu, M. (2011) · Endocrine Journal · doi:10.1507/endocrj.ej11-0064 · Cited by 11
Mori, Y., Komiya, H., Kurokawa, N., & Tajima, N. (2003) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2004.00305.x · Cited by 11
The Incretin Effect in Female Mice With Double Deletion of GLP-1 and GIP Receptors
Åhrén, B., Yamada, Y., & Seino, Y. (2019) · Journal of the Endocrine Society · doi:10.1210/jendso/bvz036 · Cited by 11
Screening of Various Parts of P haleria macrocarpa Plant for α-Glucosidase Inhibitory Activity
Sabina, E., Zaidul, I. S. M., Ghafoor, K., Jaffri, J. M., Sahena, F., Babiker, E. E., Perumal, V., Hamed, M. Z., Amid, M., & Khatib, A. (2015) · Journal of Food Biochemistry · doi:10.1111/jfbc.12212 · Cited by 11
Advances in diabetes for the millennium: understanding insulin resistance.
Gerich, J. E., & DAILEY, G. E. (2004) · PubMed Central · Cited by 10
Self-citationPathogenesis of Type 2 Diabetes Mellitus
DeFronzo, R. A. (2018) · Endocrinology · doi:10.1007/978-3-319-27317-4_8-1 · Cited by 11
Current therapeutic options in Type 2 diabetes
Heine (1999) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.1999.00004.x · Cited by 11
Cai, X., Han, X., Zhou, X., Zhou, L., Zhang, S., & Ji, L. (2017) · Journal of Diabetes Research · doi:10.1155/2017/3212814 · Cited by 10
Étiologie et physiopathologie du diabète de type 2
Rigalleau, V., Lang, J., & Gin, H. (2007) · EMC - Endocrinologie - Nutrition · doi:10.1016/s1155-1941(07)46586-6 · Cited by 10
Liu, A., Fan, Z., Lu, X., Wu, Y., Zhao, W., Lou, X., Hu, J.-H., & Peng, X. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.977278 · Cited by 9
Insulinanaloga: Struktur, Eigenschaften und therapeutische Indikationen
Rosak, C. (2001) · Der Internist · doi:10.1007/s001080170043 · Cited by 10
1 Insulin action, thermogenesis and obesity
Cooney, G. J., & Storlien, L. H. (1994) · Baillière s Clinical Endocrinology and Metabolism · doi:10.1016/s0950-351x(05)80283-6 · Cited by 10
Misawa, K., Ichikawa, K., Ojima, K., Hamano, S., Kitamura, T., & Komatsu, H. (2001) · Pharmacology · doi:10.1159/000056073 · Cited by 9
Kurebayashi, S., Watada, H., Tanaka, Y., Kawasumi, M., Kawamori, R., & Hirose, T. (2006) · Endocrine Journal · doi:10.1507/endocrj.53.213 · Cited by 10
Beta-cell secretory defect caused by mutations in glucokinase gene
Page, R. C., Hattersley, A. T., Turner, R. C., Velho, G., Clément, K., Pueyo, M. E., & Froguel, P. (1992) · The Lancet · doi:10.1016/0140-6736(92)93192-p · Cited by 10
The relationship between glucose and the liver-alpha cell axis – A systematic review
Pixner, T., Stummer, N., Schneider, A.-M., Lukas, A., Gramlinger, K., Julian, V., Thivel, D., Mörwald, K., Mangge, H., Dalus, C., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1061682 · Cited by 9
Metabolic drivers of MASLD and MASH: from hormonal imbalance to fibrosis
Gastaldelli, A., Scoditti, E., & Macedo, M. P. (2026) · Diabetologia · doi:10.1007/s00125-026-06774-7 · Cited by 11
Pathogenesis of Type 2 Diabetes
Alsahli, M., & Gerich, J. E. (2011) · Springer eBooks · doi:10.1007/978-1-4614-1028-7_7 · Cited by 8
Self-citation
Metadata
- Authors
- Mitrakou, A., Kelley, D., Mokan, M., Veneman, T., Pangburn, T., Reilly, J., & Gerich, J.
- Affiliations
- University of Pittsburgh (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1992-01-02
- Volume
- 326
- Issue
- 1
- Pages
- 22-29
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2330273698
- Cited by
- 595
- References
- 47
- Citations by year
- 2026: 12 · 2025: 5 · 2024: 9 · 2023: 11 · 2022: 15 · 2021: 15 · 2020: 13 · 2019: 13 · 2018: 14 · 2017: 20 · 2016: 12 · 2015: 27 · 2014: 25 · 2013: 18 · 2012: 19
- FWCI
- 21.07
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (7r37dk020411-19)
- National Institute of Diabetes and Digestive and Kidney Diseases (5R37 DK20411)
- National Center for Research Resources (M01RR000056, 5 M01 RR00056)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- impaired glucose tolerance, type 2 diabetes, hepatic glucose production, insulin secretion, hyperinsulinemia, glucagon, insulin/glucagon ratio, muscle glucose uptake, obesity, beta-cell dysfunction, insulin resistance
- MeSH terms
- Insulin Secretion, Blood Glucose, Diabetes Mellitus, Type 2, Female, Glucagon, Glucose Tolerance Test, Humans, Insulin, Islets of Langerhans, Liver, Male, Middle Aged, Muscles, Prediabetic State
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
